Dyslipidemia and Diabetic Retinopathy

Chang, Yo-Chen; Wu, Wen-Chuan

doi:10.1900/rds.2013.10.121

Cited by 100 publications

(82 citation statements)

References 73 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect corroborates some, but not all studies, as clinical evidence for a relation between dyslipidaemia and DR is controversial (Chang & Wu 2013). The potential mechanism of action of the association between lipids and DR is also unclear.…”

Section: Discussionsupporting

confidence: 86%

“…It has been hypothesized that lipoproteins leak through the disrupted blood–retinal barrier and have a cytotoxic effect on retinal cells (Yu & Lyons 2013). Others hypothesized that lipoproteins interact with the activation of protein kinase C and advanced glycation end product formation – two pathways involved in DR pathophysiology (Chang & Wu 2013). …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus

Schreur

Asten

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo investigate risk factors for the development and progression of diabetic retinopathy (DR) and long‐term visual outcomes in Dutch patients with type 1 diabetes mellitus (T1DM).MethodsCumulative incidences were calculated for DR, vision‐threatening DR (VTDR), defined as (pre)proliferative DR and diabetic macular oedema, and best‐corrected visual acuity (BCVA) <0.5 and <0.3 at the most recent eye examination. The following factors were assessed: duration of diabetes, age of onset of T1DM, gender, mean HbA1c, HbA1c variability (defined as coefficient of variation of five separate HbA1c measurements), mean arterial blood pressure, body mass index, albuminuria and lipid profile. We used multivariable Cox regression models to identify factors associated with DR development and progression to VTDR.ResultsWe found 25‐year cumulative incidences of 63% for DR, 21% for VTDR, 2% for BCVA <0.5, and 1% for BCVA <0.3. Mean HbA1c (HR 1.023, p < 0.001), HbA1c variability (HR 1.054, p < 0.001), age of onset of T1DM (HR 1.024, p < 0.001), HDL cholesterol (HR 0.502, p = 0.002) and total cholesterol (HR 1.210, p = 0.029) showed an independent association with faster development of any form of DR. The mean HbA1c (HR 1.023, p < 0.001) and the presence of albuminuria (HR 2.940, p = 0.028) were associated with faster progression to VTDR.ConclusionThese data show relatively low cumulative incidences of DR, VTDR and visual impairment. Higher mean HbA1c, HbA1c variability, age of onset of T1DM and total cholesterol were independently associated with the risk of DR development, and a protective association was found for HDL cholesterol in subjects with T1DM. Mean HbA1c and presence of albuminuria were associated with progression of DR.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus

Schreur

Asten

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…While there is irrefutable evidence for the role of dyslipidemia in the progression of DR ( 9,15 ), bioactive lipid metabolites have received limited attention. HETEs are major monohydroxylated AA bioactive lipid metabolites that are produced during infl ammatory and immunological reactions ( 16 ).…”

Section: Animal Preparation and Experimental Designmentioning

confidence: 99%

A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase

Ibrahim

Elshafey

Hassan

et al. 2015

Journal of Lipid Research

View full text Add to dashboard Cite

Diabetic retinopathy (DR), the most prevalent microvascular complication of diabetes, is responsible for over 10,000 new cases of blindness every year in the United States alone ( 1 ). The risk of vision loss increases with the development of diabetic macular edema and/or retinal neovascularization (NV), the former being a direct consequence of blood-retinal barrier (BRB) dysfunction and the latter the result of widespread retinal ischemia ( 2 ).For years, signifi cant effort has been invested in elucidating the mechanisms that underlie destructive preretinal NV in DR ( 3 ). Nonetheless, considerably less is known about the molecular events that lead to BRB dysfunction that is characterized by enhanced retinal vascular permeability and recruitment of infl ammatory cells. Moreover, existing regimens of treatment carry nonspecifi c adverse effects. These include increased risk of thromboembolic incidence, neuronal toxicity, and geographic atrophy with anti-vascular endothelial growth factor (VEGF) therapies

show abstract

“…It remains the leading cause of legal blindness in the working-age population in Western societies [2] and is a result of multiple pathogenetic processes caused by hyperglycemia and abnormalities of insulin signaling pathways [3], leading to retinal microvascular defects and neuroretinal dysfunction and degeneration [4]. DR is classified into non-proliferative DR (NPDR) and proliferative DR (PDR) [5].…”

Section: Introductionmentioning

confidence: 99%

Serum MiRNA Biomarkers serve as a Fingerprint for Proliferative Diabetic Retinopathy

Shao

Yuan

Chen

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Diabetic retinopathy (DR) is a retinopathy resulting from diabetes mellitus (DM) which was classified into non-proliferative DR (NPDR) and proliferative DR (PDR). Without an early screening and effective diagnosis, patients with PDR will develop serious complications. Therefore, we sought to identify special serum microRNAs (miRNAs) that can serve as a novel non-invasive screening signature of PDR and test its specificity and sensitivity in the early diagnosis of PDR. Methods: In total, we obtained serum samples from 90 PDR cases, 90 matched NPDR patients and 20 controls. An initial screening of miRNA expression was performed through TaqMan Low Density Array (TLDA). The candidate miRNAs were validated by individual reverse transcription quantitative real-time PCR (RT-qPCR) arranged in an initial and a two-stage validation sets. Moreover, additional double-blind testing was performed in 20 patients clinically suspected of having DR to evaluate the diagnostic value and accuracy of the serum miRNA profiling system in predicting PDR. Results: Three miRNAs were significantly increased in patients with PDR compared with NPDR after the multiple stages. The areas under the receiver operating characteristic (ROC) curves of the validated three-serum miRNAs signature were 0.830, 0.803 and 0.873 in the initial and two validation sets, respectively. Combination of miR-21, miR-181c, and miR-1179 possessed a moderate ability to discrimination between PDR and NPDR with an area under ROC value of 0.89. The accuracy rate of the three-miRNA profile as PDR signature was 82.6%. Conclusions: These data provide evidence that serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.

show abstract

Dyslipidemia and Diabetic Retinopathy

Cited by 100 publications

References 73 publications

Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus

Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus

A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase

Serum MiRNA Biomarkers serve as a Fingerprint for Proliferative Diabetic Retinopathy

Contact Info

Product

Resources

About